Phase II study of alemtuzumab in XXXX .

@entity1 @entity1071 @entity390 @entity1910 @entity1353 @entity2905 @entity882 @entity1072 @entity1503 @entity281 @entity1398 @entity6444 @entity6933 @entity207 @entity221 @entity5084 @entity206
BACKGROUND: Pilot studies showed that alemtuzumab is active in @entity1071 . The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory @entity1071 . METHODS: Seventy-eight @entity1 were enrolled. The most common diagnoses were @entity1072 (n = 42 @entity1 ) and @entity6444 (n = 18 @entity1 ). Before entering the study, the @entity1 had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. @entity1 were treated for 4-12 weeks depending on disease response. All @entity1 received prophylactic @entity206 / @entity207 and @entity6933 . RESULTS: The overall response rate was 35%, the complete response (CR) rate was 13%, and the partial response (PR) rate was 22%. The median duration of response was 18 months for @entity1 achieving a CR and 7 months for @entity1 achieving a PR. The median duration of survival was 25 months for @entity1 who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84% of @entity1 and resolution of bone marrow involvement was observed in 49% of @entity1 . The most common infusion-related adverse events were @entity221 , @entity5084 , @entity1910 , @entity390 , and @entity1353 . These were most common during the first week of therapy. @entity1503 was comprised of long-lasting @entity2905 and transient @entity1398 and @entity882 . Thirty-six @entity1 (46%) experienced at least one episode of @entity221 or @entity281 . CONCLUSIONS: Alemtuzumab has a high response rate in @entity1 with @entity1071 .
